The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

NCT06958627 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

964

Enrollment

OTHER

Sponsor class

Conditions

HER2 Positive Breast Cancer
Pyrotinib Treatment

Interventions

DRUG: pyrotinib

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences